Tesamorelin

Tesamorelin is a GHRH analogue studied in adults with HIV-associated abdominal fat. Egrifta WR is a specific FDA-approved product; its label says it is not for general weight-loss management.

Explore the research

Generic research visual — not a commercial product

Compound typeModified 44-residue GHRH analogue

Evidence baseRandomized controlled HIV studies and exact-product label

Regulatory contextFDA-approved Egrifta WR for specified HIV-associated abdominal fat

Page purposeResearch overview

Why there is no compound calculator on this page

The approved Egrifta WR product has exact-vial strength, diluent, and preparation instructions. A generic research-vial/U-100 calculator cannot replace product-specific labeling or validate a different vial.

Research overview

What is Tesamorelin?

Tesamorelin is a stabilized growth-hormone-releasing-hormone analogue. The FDA-approved product Egrifta WR is intended for a particular HIV-associated lipodystrophy context, not a generic cosmetic or physique goal. It differs from Sermorelin and CJC-1295.

What has research examined?

A randomized trial in 404 adults with HIV-associated excess abdominal fat found lower visceral-adipose-tissue measurement with tesamorelin than placebo. FDA-submitted Egrifta WR labeling defines product-specific indications and explicitly says it is not for weight-loss management. Trial results do not certify separately sourced research powder.

Important limitation

HIV-specific outcomes and exact-product labeling cannot be generalized. No dosing, treatment, or preparation advice is given.

Research references

Tesamorelin in HIV-associated abdominal fat: randomized trialClinical endocrinology research
Egrifta WR FDA prescribing informationU.S. Food and Drug Administration

Calculation boundary

For research purposes only. This page is educational and is not medical or veterinary advice or a recommendation to purchase, prepare, administer, or use any product.